Evidence map›Paper›PMID 25755576›Full record

ArticleJournal of clinical and experimental hepatology2014

Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis.

Vyacheslav U Buko, Oxana Y Lukivskaya, Elena E Naruta, Elena B Belonovskaya, Horst-Dietmar Tauschel

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review.World journal of gastrointestinal pharmacology and therapeutics · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. In vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Vyacheslav U BukoDivision of Biochemical Pharmacology, Institute of Biochemistry of Biologically Active Compounds, National Academy of Sciences, BLK-50, Grodno 230030, Belarus ; School of Medical Sciences, Krakowska Str. 9, 15-875 Bialystok, Poland.
Oxana Y LukivskayaDivision of Biochemical Pharmacology, Institute of Biochemistry of Biologically Active Compounds, National Academy of Sciences, BLK-50, Grodno 230030, Belarus.
Elena E NarutaDivision of Biochemical Pharmacology, Institute of Biochemistry of Biologically Active Compounds, National Academy of Sciences, BLK-50, Grodno 230030, Belarus.
Elena B BelonovskayaDivision of Biochemical Pharmacology, Institute of Biochemistry of Biologically Active Compounds, National Academy of Sciences, BLK-50, Grodno 230030, Belarus.
Horst-Dietmar TauschelDr. Falk Pharma GmbH, Leinenweberstrasse 5, Freiburg 79041, Germany.
Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus · BYDr Falk Pharma (Germany) · DEMedical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesEffects of norursodeoxycholic acid (norUDCA) and ursodeoxycholic acid (UDCA) on liver fibrosis progression and liver fibrosis reversal in thioacetamide (TAA)-treated rats were studied.

methodsAdvanced liver fibrosis was induced by TAA treatment (200 mg/kg, i.p.) for 12 weeks. In the second experiment resolution of liver fibrosis was assessed after 8 weeks of TAA withdrawal. During 8 last weeks of each trial, fibrotic rats were daily administered with UDCA (80 mg/kg) and norUDCA (equimolar to 80 mg/kg of UDCA) by oral gavage. Liver fibrosis was assessed by Sirius red staining, liver hydroxyproline and serum fibrosis markers determination.

resultsThe TAA treatment resulted in advanced fibrosis and increase in liver hydroxyproline content and serum fibrosis markers. These signs of fibrosis were less pronounced in rats after TAA withdrawal. Treatment with of norUDCA significantly decreased the total and relative liver hydroxyproline contents in rats with fibrosis reversal, whereas UDCA did not change these parameters. Both compounds decreased serum TGFβ and type IV collagen contents, whereas other serum markers did not differ from the placebo group. In the fibrosis progression model the square of connective tissue was decreased by norUDCA. Serum type IV collagen and procollagen III-NT contents in these experiments were lowered by both UDCA and norUDCA, whereas rest of serum fibrosis markers were diminished only by norUDCA.

conclusionsBoth norUDCA and UDCA showed therapeutic and prophylactic antifibrotic effect in rats with TAA-induced liver fibrosis. For most of tested parameters norUDCA was more effective than UDCA, especially in the experiment with liver fibrosis regression.

Indexed as

ALT, aminotransferaseANOVA, analysis of varianceAST, aspartate aminotransferasefibrosisliverNorUDCA, norursodeoxycholic acidnorursodeoxycholic acidSEM, standard error of the meanTAA, thioacetamidethioacetamideTIMP-1, tissue inhibitor of metalloproteinase-1UDCA, ursodeoxycholic acidursodeoxycholic acid

Identifiers

PMID25755576
PMCPMC4298626
OpenAlexW2069032909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.